Skip to main content

Table 2 Percent achievement and odds ratios for LDL-C, non-HDL-C and Apo B targets

From: Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

 

All subjects

High risk or very high risk subjects

Week 6

Week 12

Week 6

Week 12

Targets

E + A10

A20

OR

E + A10

A20/A40

OR

E + A10

A20

OR

E + A10

A20/A40

OR

(mmol/L) for LDL-C, non-HDL-C; g/L for Apo B

            

Canadian

(N = 515)

(N = 515)

 

(N = 516)

(N = 509)

       

Single

LDL-C ≤2.0

62.3

31.1

3.67 *

60.5

49.7

1.55 *

 

non-HDL-C ≤2.6

62.3

35.9

2.95 *

58.5

49.7

1.43 *

Apo B ≤0.8

47.7

31.1

2.02 *

44.6

38.1

1.31 *

Dual/Triple

LDL-C ≤2.0, non-HDL-C ≤2.6

57.1

25.4

3.90 *

53.1

44.2

1.43 *

 

LDL-C ≤2.0, Apo B ≤1.0

45.2

21.6

2.99 *

41.7

35.2

1.32 *

LDL-C ≤2.0, non-HDL ≤2.6, Apo B ≤0.8

44.8

20.6

3.12 *

41.3

34.8

1.32 *

EU-High Risk

(N = 515)

(N = 515)

 

(N = 516)

(N = 516)

 

(n = 66)

(n = 67)

 

(n = 67)

(n = 67)

 

Single

LDL-C <2.5

85.2

72.6

2.18 *

82.4

77.0

1.39 *

68.2

50.7

2.08 *

61.2

61.2

1.00

non-HDL-C <3.3

86.2

78.1

1.76 *

84.1

81.9

1.17

68.2

59.7

1.45

68.7

70.1

0.93

Apo B <1.0

78.3

69.5

1.59 *

74.8

71.5

1.18

58.7

48.5

1.51

53.8

53.0

1.03

Dual/Triple

LDL-C <2.5, non-HDL-C <3.3

83.9

70.3

2.20 *

81.0

74.3

1.48 *

66.7

50.7

1.94

61.2

58.2

1.13

LDL-C <2.5, Apo B <1.0

76.3

63.6

1.84 *

72.8

67.8

1.27

55.6

40.9

1.81

49.2

50.0

0.97

LDL-C <2.5, non-HDL <3.3, Apo B <1.0

75.9

63.0

1.85 *

72.6

67.2

1.29

55.6

40.9

1.81

49.2

50.0

0.97

EU-Very High Risk

(N = 515)

(N = 515)

 

(N = 516)

(N = 516)

 

(n = 449)

(n = 448)

 

(n = 449)

(n = 442)

 

Single

LDL-C <1.8

47.4

17.9

4.14 *

43.6

32.2

1.63 *

50.8

20.1

4.10 *

47.2

35.3

1.64 *

Non-HDL-C <2.6

62.3

35.9

2.95 *

58.5

49.7

1.43 *

66.1

39.7

2.96 *

62.6

52.5

1.51 *

Apo B <0.8

45.4

28.0

2.13 *

43.8

35.4

1.43 *

48.9

30.8

2.15 *

46.9

37.7

1.46 *

Dual/Triple

LDL-C <1.8, non-HDL-C <2.6

45.4

15.1

46.7 *

41.3

30.1

1.64 *

48.8

17.4

4.52 *

45.0

32.8

1.68 *

LDL-C <1.8, Apo B <0.8

38.7

14.4

3.75 *

35.2

25.9

1.56 *

41.4

16.3

3.64 *

38.1

28.2

1.57 *

LDL-C <1.8, non-HDL <2.6, Apo B <0.8

38.3

13.6

3.93 *

35.2

25.7

1.57 *

41.0

15.6

3.75 *

38.1

28.0

1.59 *

  1. N may vary slightly between measured parameters due to differences in available data.
  2. *OR considered significant based on associated 95% confidence interval which excludes 1.
  3. A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular disease; Canadian, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe 10 mg; EU, European Guidelines (2012); LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; OR, odds ratio.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X